title: Unpicking the combination lock for mutant BRAF and RAS melanomas.
abstract: Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
authors: Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Bissan.Al-Lazikani@icr.ac.uk
authors: Bissan
authors: B
authors: Al-Lazikani
authors: Paul
authors: P
authors: Workman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D018631:ras Proteins